Detalles de la búsqueda
1.
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Cancer Invest
; 41(6): 571-592, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272675
2.
Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.
Future Oncol
; 19(33): 2237-2250, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37529892
3.
Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced/metastatic non-small cell lung cancer in the EU5.
Thorac Cancer
; 14(28): 2846-2858, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592826
4.
Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".
Am J Manag Care
; 25(4): 171-172, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30986013
5.
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
J Med Econ
; 21(5): 497-509, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29376760
6.
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
Am J Manag Care
; 24(8 Suppl): S132-S137, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693359
7.
Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Am J Manag Care
; 24(8 Suppl): S138-S145, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693360
8.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Am J Manag Care
; 24(8 Suppl): S146-S155, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693361
9.
Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas.
Am Health Drug Benefits
; 10(4): 165-174, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28794821
10.
Economic burden of comorbid chronic kidney disease and diabetes.
J Med Econ
; 20(6): 585-591, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28128669
11.
Patient preferences for diabetes treatment attributes and drug classes.
Curr Med Res Opin
; 33(2): 261-268, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27779433
12.
Quality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studies.
Risk Manag Healthc Policy
; 9: 231-241, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27790048
13.
The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data.
Arch Public Health
; 72(1): 6, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24576356
14.
Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: a retrospective observational cohort study using administrative claims data.
Expert Rev Endocrinol Metab
; 9(2): 183-191, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30743760
15.
Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.
J Manag Care Spec Pharm
; 20(4): 391-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24684644
16.
Predictors of medication adherence in patients with type 2 diabetes mellitus.
Curr Med Res Opin
; 29(10): 1275-86, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23815104
Resultados
1 -
16
de 16
1
Próxima >
>>